References
- Cada DJ, Levien TL, Baker DE. Sugammadex. Hosp Pharm [Internet]. 2016 [cited 2019 Jul 30];51:585–596. Available from http://www.ncbi.nlm.nih.gov/pubmed/27559192.
- Farooq K, Hunter JM. Neuromuscular blocking agents and reversal agents. Anaesth. Intensive Care Med [Internet]. 2011 [cited 2019 Jun 13];12:266–270. Available from https://www.sciencedirect.com/science/article/abs/pii/S1472029911000609.
- D’Souza RS, Johnson RL. Nondepolarizing Paralytics [Internet]. In: StatPearls. Layer D, editor. StatPearls Publishing; 2019 [cited 2019 Aug 2]. Available from http://www.ncbi.nlm.nih.gov/pubmed/30137795. PMID: 30725853.
- Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg [Internet]. 2010 [cited 2019 Jun 13];110:64–73. Available from http://www.ncbi.nlm.nih.gov/pubmed/19713265.
- Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol [Internet]. 2010 [cited 2019 Jun 13];27:874–881. Available from http://www.ncbi.nlm.nih.gov/pubmed/20683334.
- Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium. Anesthesiology [Internet]. 2009 [cited 2019 Jun 13];110:1020–1025. Available from http://www.ncbi.nlm.nih.gov/pubmed/19387176.